“A large number of pipeline agents with innovative approaches are under investigation for adjuvant, intermediate, and advanced therapy [for hepatocellular carcinoma].” Mandana Emamzadeh of GlobalData
Cell-based therapies could provide an advantageous alternative, but the development of these new therapies is often impaired and delayed by the lack of an appropriate model to test their safety and efficacy in humans before embarking in clinical trials.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.